Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2021, Vol. 48 Issue (2): 299-306    DOI: 10.31083/j.ceog.2021.02.2275
Original Research Previous articles | Next articles
Paternal age predicts live birth in women above 40 years of age undergoing in-vitro fertilization (IVF)
Guy Shrem1, 2, Nouf M. Alasmari2, Jacques Balayla1, Alexander Volodarsky-Perel1, 2, Weon-Young Son2, Michael H. Dahan1, 2, *()
1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, McGill University, 845 Rue Sherbrooke O, Montréal, QC H3A 0G4, Canada
2MUHC Reproductive Center, McGill University, 888 Boul de Maisonneuve E #200, Montréal, QC H2L 4S8, Canada
Download:  PDF(273KB)  ( 116 ) Full text   ( 10 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Purpose: To determine which factors predict pregnancy outcome in women aged 40 years and above who underwent in-vitro fertilization. Method: We conducted a retrospective case-control study of 631 women aged 40–46 years, who underwent a total of 904 IVF cycles with autologous gametes. We used stepwise logistic regression analysis to develop predictors of pregnancy, clinical pregnancy and live birth outcomes. Data are presented as mean ± SD, percentage and confidence intervals. Results: Predictors of live birth included maternal (95% CI: 0.36–0.78) and paternal (95% CI: 0.62–0.94) age, the number of follicels > 14 mm (95% CI: 1.2–3.2), the number of oocytes collected (95% CI: 1.3–2.9) the number of metaphase II oocytes (95% CI: 1.3–2.4) and the number of cleavage stage embryos (95% CI: 1.8–2.6). The predictors of pregnancy and clinical pregnancy were similar but did not include male age (P > 0.05). To further determine the role of male age in live birth a control group of women younger than 40 years was collected. Male age was not a significant predictor of live birth among younger women (P = 0.42). Conclusions: Female age and better ovarian stimulation were confirmed as predictors of outcomes in older women doing IVF. However, male age was also noted to be a significant individual predictor of live birth in women over 40 years of age, but not in younger women doing IVF.
Key words:  Advanced maternal age      Advanced paternal age      Biologic clock      IVF      In-vitro fertilization     
Submitted:  28 August 2020      Revised:  21 October 2020      Accepted:  20 November 2020      Published:  15 April 2021     
*Corresponding Author(s):  Michael H. Dahan     E-mail:  dahanhaim@hotmail.com

Cite this article: 

Guy Shrem, Nouf M. Alasmari, Jacques Balayla, Alexander Volodarsky-Perel, Weon-Young Son, Michael H. Dahan. Paternal age predicts live birth in women above 40 years of age undergoing in-vitro fertilization (IVF). Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 299-306.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2021.02.2275     OR     https://ceog.imrpress.com/EN/Y2021/V48/I2/299

[1] Z. Merhi, J. Zhang. At-Home IVF Kit: application during the COVID-19 pandemic[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(5): 653-659.
[2] S. J. Knight, A. D. Smith, H. Kim, A. C. Collier. Human placental suppressors of cytokine signalling (SOCS) and inflammatory cytokines are dysregulated in assisted reproduction, advanced maternal age and pre-term birth[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 277-286.
[3] C. Chan, J.W. Wang, C.W. Wang, C.W. Chang. A pitfall in ultrasonographic diagnosis–heterotopic cornual pregnancy initially misdiagnosed as leiomyoma[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 296-298.
[4] M.S. Jo, H.J. Lee, Y.J. Lee, S.C. Kim, J.K. Joo, K.S. Lee. Which is the safer method for trophectoderm biopsy in mouse blastocyst, mechanical or laser?[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(1): 27-30.
[5] E.G. Aydeniz, U. Sari, T.U.K. Dilek. Pregnancy success rate at recurrent implantation failure patients after hysteroscopic endometrial injury: preliminary study[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 709-712.
[6] P. Bakas, M. Simopoulou, P. Panagopoulos, N. Salakos, Ch. Siristatidis. Luteal phase progesterone and estradiol concentrations and their relation to the outcome of IVF/ICSI cycles with controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 727-730.
[7] B. Luo, L. Luo. Simultaneous cornual heterotopic and intrauterine pregnancy following in vitro fertilization/embryo transfer: new conservative surgery with laparoscopic lesion resection[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 482-484.
[8] M. Collict, Y. Mucat Baron, M. Gatt, N. Calleja. Advanced maternal age and neonatal outcomes in Malta[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 265-269.
[9] J.-K. Joo, J.-E. Jeong, H.-G. Kim, S.-C. Kim, C.-W. Kim, K.-S. Lee. Effect of laser-assisted three area zona thinning at the 8-cell embryo on the hatching of mouse blastocysts[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 231-234.
[10] Chunjuan Shen, Liping Wang, Xiaojie Wu, Shuhui Mao, Chunxia Fang. The relationship between vitamin D and IVF: a systematic review and meta-analysis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 12-15.
[11] B. Díaz-Rabasa, R. Crespo Esteras, A. Agustín-Oliva, R.A. Laborda Gotor, P. Tobías González, C. De Bonrostro Torralba, S. Castán Mateo. Has advanced maternal age a real impact on intrapartum caesarean rate?[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(1): 55-59.
[12] R. La Torre, S. Grisolia, V. D'Ambrosio, E. Marcoccia, S. Gatto, A. Squarcella, C. Aliberti, F. Colloridi, F. Rech, A. Giancotti. Advanced maternal age and pregnancy outcome: experience in a tertiary care center[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(3): 334-338.
[13] M.B. Celtemen, P. Telli Celtemen, N. Bozkurt, C. Karakaya, S. Elberg, R.H. Gursoy. Follicular fluid anti-Müllerian hormone, inhibin-A, progesterone, and estradiol level differences in patients under controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 166-169.
[14] Bo Ma, Yuhu Li, Xiulan Zhang, Liuguang Zhang, Ning Li, Ping Yu. Supplementation of IVF solutions with melatonin improves assisted reproductive technology results[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 209-213.
[15] P. Bakas, M. Creatsa, P. Panagopoulos, N. Vlahos, E. Papadakis, M. Simopoulou. Outcome and recurrence risk of premature progesterone rise in IVF/ICSI cycles using GnRH antagonists for pituitary down-regulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(1): 44-47.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] Sandeep K. Krishnan, Norman E. Lepor. Acute and Chronic Cardiovascular Effects of Hyperkalemia: New Insights Into Prevention and Clinical Management[J]. Reviews in Cardiovascular Medicine, 2016, 17(S1): 9 -21 .
[3] Ibrahim Sidiqi, Patrick Alexander. Current Advances in Endovascular Therapy for Infrapopliteal Artery Disease[J]. Reviews in Cardiovascular Medicine, 2015, 16(1): 36 -50 .
[4] Prakash C. Deedwania. Management of Patients With Stable Angina and Type 2 Diabetes[J]. Reviews in Cardiovascular Medicine, 2015, 16(2): 105 -113 .
[5] Peter Shalit. Management of Dyslipidemia in Patients With Human Immunodeficiency Virus[J]. Reviews in Cardiovascular Medicine, 2014, 15(S1): 38 -46 .
[6] Sophie Mavrogeni, Fabrizio Cantini, Gerald M. Pohost. Systemic Vasculitis: An Underestimated Cause of Heart Failure—Assessment by Cardiovascular Magnetic Resonance[J]. Reviews in Cardiovascular Medicine, 2013, 14(1): 49 -55 .
[7] George L. Smith. Appropriate Use Criteria: The Gold Standard, or a Mechanism for the Derogation of Clinical Judgment?[J]. Reviews in Cardiovascular Medicine, 2011, 12(2): 105 .
[8] Jeffrey W. Moses, Stephane Carlier, Issam Moussa. Lesion Preparation Prior to Stenting[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 16 -21 .
[9] Dean J. Kereiakes. Coronary Small-Vessel Stenting in the Era of Drug Elution[J]. Reviews in Cardiovascular Medicine, 2004, 5(S2): 34 -45 .
[10] Steven V. Edelman. The Role of the Thiazolidinediones in the Practical Management of Patients With Type 2 Diabetes and Cardiovascular Risk Factors[J]. Reviews in Cardiovascular Medicine, 2003, 4(S6): 29 -37 .